Psoriatic Arthritis News and Research

RSS

Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

WHO member states recognize psoriasis as chronic, non-communicable disease

At the 67th World Health Assembly, the WHO member states adopted a resolution on psoriasis, recognizing it as "a chronic, non-communicable, painful, disfiguring, and disabling disease for which there is no cure."

27 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease.

6 May 2014

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen today announced it has initiated a Phase Ib/IIa study with COVA322, a bispecific TNF/IL-17A inhibitor.

6 May 2014

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

To improve treatment decisions and patient outcomes for psoriatic arthritis (PsA)—a chronic inflammatory arthritis that affects the joints and tendons—the National Psoriasis Foundation and Corrona, LLC are collaborating to give NPF-affiliated researchers access to Corrona’s psoriatic arthritis registry, which is the largest psoriatic arthritis registry in the world.

25 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

New initiative aims to develop Global Psoriasis Atlas

While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization, reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6% .

15 Apr 2014

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

A panel of leading experts representing different sectors of the health care community met to discuss the significant and underestimated burden psoriasis and psoriatic arthritis have on patients, the health care system and economy, and the impact medical innovation has on reducing these burdens.

1 Apr 2014

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

News outlets report on the creative outreach efforts, including those geared to moms, young people and Latinos, to increase the number of newly insured people before March 31. Even prison inmates are signing up.

11 Mar 2014

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.

10 Mar 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

Psoriasis is the most common autoimmune disease in the US, affecting 2 to 3% of all Americans. What causes psoriasis in any one individual will stem from a mixture of their genetic background and their environment.

4 Feb 2014

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis Foundation and the Consortium of Rheumatology Researchers of North America, Inc. will create the first psoriasis registry co-developed and co-administered by a nonprofit.

10 Jan 2014

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women with chronic autoimmune diseases who take immunosuppressive medications during their first trimester of pregnancy are not putting their babies at significantly increased risk of adverse outcomes, according to a Vanderbilt study released online by the journal Arthritis and Rheumatism.

11 Nov 2013

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

Researchers have linked a species of intestinal bacteria known as Prevotella copri to the onset of rheumatoid arthritis, the first demonstration in humans that the chronic inflammatory joint disease may be mediated in part by specific intestinal bacteria.

6 Nov 2013

IFPA brings attention to the need for improving treatment, care for psoriasis

Today, on World Psoriasis Day, the International Federation of Psoriasis Associations, IFPA, brings attention to the need for improving the availability of treatment and care for psoriasis - a disease that affects more than 125 million people all over the world.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.

29 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Psoriatic Arthritis News and Research

Further Reading

WHO member states recognize psoriasis as chronic, non-communicable disease

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

New initiative aims to develop Global Psoriasis Atlas

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Alvogen launches Inflectra into Central and Eastern Europe

Psoriasis registry: an interview with Dr. Andrew D. Robertson, Chief Scientific and Medical Officer, National Psoriasis Foundation

NPF, CORRONA to create first psoriasis registry to improve treatments and patient outcomes

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Researchers link species of intestinal bacteria to onset of rheumatoid arthritis

IFPA brings attention to the need for improving treatment, care for psoriasis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News